
[Federal Register Volume 82, Number 121 (Monday, June 26, 2017)]
[Notices]
[Page 28860]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-13236]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2017-N-0809]


Issuance of Priority Review Voucher; Rare Pediatric Disease 
Product

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is announcing the 
issuance of a priority review voucher to the sponsor of a rare 
pediatric disease product application. The Federal Food, Drug, and 
Cosmetic Act (the FD&C Act), as amended by the Food and Drug 
Administration Safety and Innovation Act (FDASIA), authorizes FDA to 
award priority review vouchers to sponsors of approved rare pediatric 
disease product applications that meet certain criteria. FDA is 
required to publish notice of the award of the priority review voucher. 
FDA has determined that Brineura (cerliponase alfa) manufactured by 
Biomarin Pharmaceuticals Inc., meets the criteria for a priority review 
voucher.

FOR FURTHER INFORMATION CONTACT: Althea Cuff, Center for Drug 
Evaluation and Research, Food and Drug Administration, 10903 New 
Hampshire Ave., Bldg. 22, Rm. 6484, Silver Spring, MD 20993-0002, 301-
796-4061, FAX: 301-796-9858, email: althea.cuff@fda.hhs.gov.

SUPPLEMENTARY INFORMATION: FDA is announcing the issuance of a priority 
review voucher to the sponsor of an approved rare pediatric disease 
product application. Under section 529 of the FD&C Act (21 U.S.C. 
360ff), which was added by FDASIA, FDA will award priority review 
vouchers to sponsors of approved rare pediatric disease product 
applications that meet certain criteria. FDA has determined that 
Brineura (cerliponase alfa) manufactured by Biomarin Pharmaceuticals 
Inc., meets the criteria for a priority review voucher. Brineura 
(cerliponase alfa) is indicated to slow the progression of loss of 
ambulation in symptomatic pediatric patients 3 years of age and older 
with late infantile neuronal ceroid lipofuscinosis type 2 (CLN2), also 
known as tripeptidyl peptidase 1 (TPP1) deficiency.
    For further information about the Rare Pediatric Disease Priority 
Review Voucher Program and for a link to the full text of section 529 
of the FD&C Act, go to https://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions/RarePediatricDiseasePriorityVoucherProgram/default.htm. For further 
information about Brineura (cerliponase alfa) go to the ``Drugs@FDA'' 
Web site at https://www.accessdata.fda.gov/scripts/cder/daf/.

    Dated: June 20, 2017.
Anna K. Abram,
Deputy Commissioner for Policy, Planning, Legislation, and Analysis.
[FR Doc. 2017-13236 Filed 6-23-17; 8:45 am]
BILLING CODE 4164-01-P


